Eton Pharmaceuticals delivered one of its cleanest operating quarters to date, though the headline number needs unpacking. The rare-disease company reported third-quarter GAAP earnings of $1.06 per share on revenue of $57.93 million. That beat the $0.34 consensus by 211.8% and the $42.21 million revenue estimate by 37.2%. Earnings grew 1614.3% year over year, a swing from a $0.07 loss in the prior-year quarter, while revenue grew 157.9%. Management also raised 2026 revenue guidance to more than $175 million from more than $145 million and lifted its adjusted EBITDA margin target to above 40% from above 35%. It was the third straight quarterly increase in both.

The quality of the EPS beat deserves scrutiny. Roughly $12.9 million of the $35.2 million in GAAP net income came from releasing the valuation allowance on federal and some state deferred tax assets. That is a one-time benefit, not operating performance. Strip it out, and non-GAAP EPS was $0.50. Even that figure clears the consensus by a wide margin, so the beat is real, but the GAAP surprise percentage overstates it. Underneath the accounting, the operating story is genuinely strong:

• Adjusted gross margin reached 80%, up from 45% a year ago and 73% in the second quarter.
• Adjusted EBITDA was $28.5 million, a 49% margin, versus 43% in Q2 and 24% in Q1.
• Operating income was $23.0 million, compared with a $1.4 million loss a year earlier.

Much of this reflects mix and operating leverage, with HEMANGEOL contributing its first full quarter at a net price at or slightly above the top of the $8,000-$10,000 range.

The trajectory matters more than any single quarter. Revenue climbed from $24.3 million in Q1 to $37.6 million in Q2 and then $57.9 million in Q3, so growth accelerated sharply through the year. Part of that step-up is acquisition-driven, since HEMANGEOL was not in the base a year ago. Still, management reported record active patient counts for every key promoted product: INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, DESMODA and HEMANGEOL. That points to organic volume growth, not just bolt-on revenue. Eton passed its $200 million annualized run-rate goal five quarters early and signaled that its $500 million 2030 target could be reached sooner. Its 50% adjusted EBITDA margin goal for 2028 is essentially already in hand.

The guidance carries some nuance:

• **Implied Q4.** With $119.8 million booked through nine months, the new full-year floor implies fourth-quarter revenue of only about $55 million, slightly below Q3. That looks conservative.
• **Gross margin.** The press release calls for full-year adjusted gross margin above 70%, while the call pointed to roughly 75%.
• **Q4 costs.** A one-time $4 million ALKINDI milestone will run through fourth-quarter cost of sales, and management warned that EBITDA margins may fluctuate with R&D timing.
• **Spending.** G&A rose 98% year over year on stock compensation, headcount and the loss of the orphan-drug FDA fee exemption.

The pipeline broadened but also took its first visible setback. The new catalysts are substantial:

• LIBERVANT, a buccal diazepam film, has a March 29, 2027 PDUFA date and targets an April 2027 launch into a U.S. seizure-rescue market estimated above $450 million.
• KHINDIVI's label expansion has a May 28, 2027 PDUFA date.
• The Glyburide Oral Suspension NDA is expected around year-end.
• ASN-001, which management believes could become its largest product, enters bioavailability dosing in January.
• The INCRELEX harmonization study could expand the addressable U.S. population from about 200 to 1,000 patients.

The counterweight is ET-700. It was far better tolerated than GALZIN (1 of 12 versus 8 of 12 treatment-related adverse events) but cut hepatic copper uptake by only 12%, versus 46% for GALZIN. The planned early-2027 pivotal start now gives way to reformulation arms around the third quarter of 2027. LIBERVANT also requires final FDA approval, exclusivity resolution and a new dedicated sales force. The new ET-900 spasms program is earlier-stage than Eton's usual approach.

The market setup is more complicated than the surprise implies. Investor sentiment moved from slightly negative (-0.04) to modestly positive (0.20) heading into the report, a meaningful improvement but hardly euphoric. The stock had been sliding even as fundamentals improved. At $50.72 on the eve of earnings, shares were down 7.7% from the open after the August report and 23.6% below the 52-week high of $66.37 set on August 24. They sat just 4.9% above the October low. They remained about 40% above the 200-day moving average, so the longer-term uptrend is intact even as the post-August spike has largely deflated. The negative AVWAP reading reflects that recent distribution, while sequential-growth and momentum readings remain positive.

The bottom line is that Eton's operating results were better than the inflated GAAP figure needed to make them look: accelerating revenue, near-80% gross margins, record cash of $55.6 million and a third consecutive guidance raise. Bears have legitimate ammunition in the one-time tax benefit, the ET-700 delay, rising G&A and a heavy 2027 regulatory calendar. Even so, a stock that entered the print near the bottom of its quarterly range has a fundamental story that now looks stronger than its recent price action.